258 related articles for article (PubMed ID: 21756848)
1. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence.
Kamimura H; Yamagiwa S; Tsuchiya A; Takamura M; Matsuda Y; Ohkoshi S; Inoue M; Wakai T; Shirai Y; Nomoto M; Aoyagi Y
J Hepatol; 2012 Feb; 56(2):381-8. PubMed ID: 21756848
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells.
Bugide S; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3509-E3518. PubMed ID: 29581297
[TBL] [Abstract][Full Text] [Related]
3. Proteasome regulation of ULBP1 transcription.
Butler JE; Moore MB; Presnell SR; Chan HW; Chalupny NJ; Lutz CT
J Immunol; 2009 May; 182(10):6600-9. PubMed ID: 19414815
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
5. Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness.
Cadoux M; Caruso S; Pham S; Gougelet A; Pophillat C; Riou R; Loesch R; Colnot S; Nguyen CT; Calderaro J; Celton-Morizur S; Guerra N; Zucman-Rossi J; Desdouets C; Couty JP
J Hepatol; 2021 Jun; 74(6):1386-1397. PubMed ID: 33484773
[TBL] [Abstract][Full Text] [Related]
6. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
[TBL] [Abstract][Full Text] [Related]
7. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
[TBL] [Abstract][Full Text] [Related]
8. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity.
Cheung PF; Yip CW; Wong NC; Fong DY; Ng LW; Wan AM; Wong CK; Cheung TT; Ng IO; Poon RT; Fan ST; Cheung ST
Cancer Immunol Res; 2014 Dec; 2(12):1209-19. PubMed ID: 25315249
[TBL] [Abstract][Full Text] [Related]
9. Post-transcriptional regulation of ULBP1 ligand for the activating immunoreceptor NKG2D involves 3' untranslated region.
Himmelreich H; Mathys A; Wodnar-Filipowicz A; Kalberer CP
Hum Immunol; 2011 Jun; 72(6):470-8. PubMed ID: 21406206
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
11. Clinical Impact of Natural Killer Group 2D Receptor Expression and That of Its Ligand in Ovarian Carcinomas: A Retrospective Study.
Lee GH; An HJ; Kim TH; Kim G; Park KS; Park H; Lee TH; Kwon AY
Yonsei Med J; 2021 Apr; 62(4):288-297. PubMed ID: 33779082
[TBL] [Abstract][Full Text] [Related]
12. A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells.
Gowen BG; Chim B; Marceau CD; Greene TT; Burr P; Gonzalez JR; Hesser CR; Dietzen PA; Russell T; Iannello A; Coscoy L; Sentman CL; Carette JE; Muljo SA; Raulet DH
Elife; 2015 Nov; 4():. PubMed ID: 26565589
[TBL] [Abstract][Full Text] [Related]
13. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.
Shin S; Kim M; Lee SJ; Park KS; Lee CH
Cancer Genomics Proteomics; 2017; 14(5):349-362. PubMed ID: 28871002
[TBL] [Abstract][Full Text] [Related]
14. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
[TBL] [Abstract][Full Text] [Related]
15. c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis.
Nanbakhsh A; Pochon C; Mallavialle A; Amsellem S; Bourhis JH; Chouaib S
Blood; 2014 Jun; 123(23):3585-95. PubMed ID: 24677544
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
[TBL] [Abstract][Full Text] [Related]
17. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
18. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.
López-Soto A; Folgueras AR; Seto E; Gonzalez S
Oncogene; 2009 Jun; 28(25):2370-82. PubMed ID: 19430493
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.
Bae JH; Kim SJ; Kim MJ; Oh SO; Chung JS; Kim SH; Kang CD
Cancer Sci; 2012 Jan; 103(1):7-16. PubMed ID: 21951556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
